Women And Heart Disease

This is a groundbreaking book which explains the important clinical and surgical aspects of the diagnosis and treatment of heart disease in women, and seeks to improve the understanding of the difference gender makes to both the presentation of heart disease and the disease itself.

Heart disease remains the number one killer of women in the United States. It kills more women than breast and lung cancer combined. This book aims to educate women about heart disease, risk factors, signs and symptoms of a heart attack. It also teaches lifestyle habits that can be adopted to prevent heart disease.

Despite being one of the world's biggest killers of women, heart disease is under-diagnosed, under-treated, and under-managed. Why? What is going wrong? Important and ground-breaking, Women and Heart Disease brings our attention to the inadequacies in both the diagnosis and treatment of heart disease in women. Key features: * written by Nanette Wenger and Peter Collins, two of the worlds leading cardiologists * contributions from leaders in women‘s cardiac health * covers all aspects of cardiovascular disease, not just coronary artery disease * fully updated. Building on the success of the best-selling first edition, this is essential reading for all physicians with a particular interest in women and heart disease.

Chronic diseases are common and costly, yet they are also among the most preventable health problems. Comprehensive and accurate disease surveillance systems are needed to implement successful efforts which will reduce the burden of chronic diseases on the U.S. population. A number of sources of surveillance data--including population surveys, cohort studies, disease registries, administrative health data, and vital statistics--contribute critical information about chronic disease. But no central surveillance system provides the information needed to analyze how chronic disease impacts the U.S. population, to identify public health priorities, or to track the progress of preventive efforts. A Nationwide Framework for Surveillance of Cardiovascular and Chronic Lung Diseases outlines a conceptual framework for building a national chronic disease surveillance system focused primarily on cardiovascular and chronic lung diseases. This system should be capable of providing data on disparities in incidence and prevalence of the diseases by race, ethnicity, socioeconomic status, and geographic region, along with data on disease risk factors, clinical care delivery, and functional health outcomes. This coordinated surveillance system is needed to integrate and expand existing information across the multiple levels of decision making in order to generate actionable, timely knowledge for a range of stakeholders at the local, state or regional, and national levels. The recommendations presented in A Nationwide Framework for Surveillance of Cardiovascular and Chronic Lung Diseases focus on data collection, resource allocation, monitoring activities, and implementation. The report also recommends that systems evolve along with new knowledge about emerging risk factors, advancing technologies, and new understanding of the basis for disease. This report will inform decision-making among federal health agencies, especially the Department of Health and Human Services; public health and clinical practitioners; non-governmental organizations; and policy makers, among others.

Discusses the heart and heart disease in terms of incidence, risk factors, prevention, and treatment in women.

Whether you're a freshly diagnosed patient, a woman who's been living with heart disease for years, or a practitioner who cares about women's health, A Woman's Guide to Living with Heart Disease will help you feel less alone and advocate for better health care.

Reactive oxygen species (ROS) influence various physiological processes including host defense, hormone biosynthesis, and cellular signaling. Increased ROS production (oxidative stress) is implicated in many diseases of the cardiovascular system, including hypertension, atherosclerosis, cardiac failure, stroke, diabetes, and kidney disease. ROS are produced throughout the cardiovascular system, in the kidney and central and peripheral nervous system. A major source for cardiovascular, renal, and neural ROS is a family of non-phagocytic NAD(P)H oxidases, including the prototypic Nox2 homologue-based NAD(P)H oxidase, as well as other NAD(P)H oxidases, such as Nox1 and Nox4. Other possible sources include mitochondrial electron transport enzymes, xanthine oxidase, cyclooxygenase, lipoxygenase, and uncoupled nitric oxide synthase (NOS). NAD(P)H oxidase-derived ROS is important in regulating endothelial function and vascular tone and oxidative stress is implicated in endothelial dysfunction, inflammation, hypertrophy, apoptosis, migration, fibrosis, angiogenesis and rarefaction, important processes involved in vascular remodeling in cardiovascular disease. These findings have evoked considerable interest because of the possibilities that therapies targeted against non-phagocytic NAD(P)H oxidase to decrease ROS generation and/or strategies to increase nitric oxide (NO) availability and antioxidants may be useful in minimizing vascular injury and thereby prevent or regress target organ damage associated with hypertension and other cardiovascular diseases.

Despite media attention and public awareness, recent advances in pharmaceutical and medical developments, heart disease in women is under-diagnosed, under-treated, and under-managed. Many women fail to present in the clinic when symptomatic, because of responsibilities at home or at work. Often the first presentation follows a cardiac event. Women are excluded from many clinical trials regardless of age or cardiac history, simply because most trials are aimed at male patients. This best-selling, updated title, aimed at changing this treatment of women's cardiac issues, covers all aspects of female cardiovascular disease. It is required reading for all practitioners who assess female patients.